Stratec (SBS) Panoramica del titolo
Stratec SE, insieme alle sue consociate, progetta e produce soluzioni di automazione e strumentazione nei settori della diagnostica in vitro e delle scienze della vita in Germania, nell'Unione Europea e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 1/6 |
SBS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Stratec SE
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €17.68 |
| Massimo di 52 settimane | €33.10 |
| Minimo di 52 settimane | €16.30 |
| Beta | 0.79 |
| Variazione di 1 mese | 0.45% |
| Variazione a 3 mesi | -14.38% |
| Variazione di 1 anno | -37.31% |
| Variazione a 3 anni | -70.73% |
| Variazione a 5 anni | -83.29% |
| Variazione dall'IPO | 239.80% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento della narrazione • May 08
SBS: Lower Growth Assumptions Will Still Allow Future Upside Potential
The analyst fair value estimate for Stratec has been revised from about €26.00 to about €20.00, as analysts trim price targets and factor in lower revenue growth assumptions, softer profit margin expectations, and a higher implied future P/E, in line with recent target cuts from major banks. Analyst Commentary Recent Street research reflects a more cautious stance on Stratec, with price targets revised lower and expectations reset around revenue growth and profitability.
Aggiornamento della narrazione • Apr 21
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.
Aggiornamento della narrazione • Apr 06
SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.Aggiornamento della narrazione • Mar 23
SBS: Future Upside Will Depend On Repriced Earnings Power And Margins
Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.Aggiornamento della narrazione • Mar 09
SBS: Higher Discount Rate And Index Removal Will Still Allow Future Upside
Narrative Update on Stratec The analyst price target for Stratec has been reduced by €1, as analysts reflect slightly adjusted assumptions around discount rates, revenue growth and profit margins in their updated models. Analyst Commentary Bearish analysts trimming their price targets, including the recent €1 reduction, are signaling a more cautious stance on Stratec.Aggiornamento della narrazione • Feb 22
SBS: Higher Discount Rate Will Still Allow Future Upside Potential
Analysts have reduced their price target on Stratec by €1 to €26, reflecting updated assumptions regarding the company’s discount rate, revenue growth, profit margin and future P/E profile. Analyst Commentary Bearish analysts cutting the price target to €26 are signaling a more cautious stance on Stratec’s risk and reward trade off at current levels.Aggiornamento della narrazione • Feb 08
SBS: Future Upside Will Rely On Earnings Power And Cost Controls
Narrative update on Stratec Analysts have trimmed their 12 month price target on Stratec by about €1, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research updates on Stratec point to a small pullback in published price targets, with a reduction of about €1 in the latest move and a prior cut from €30 to €27.Aggiornamento della narrazione • Jan 23
SBS: Future Margin Recovery Will Rely On Efficiency Gains And Cost Controls
Analysts have trimmed their price target on Stratec, with the average moving slightly lower in line with a recent cut from €30 to €27, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research points to a more cautious stance on Stratec, with the reduced €27 price target reflecting updated views on what analysts see as fair value, the applied discount rate, revenue growth assumptions, margin profile and future P/E expectations.Articolo di analisi • Jan 10
Returns On Capital Signal Tricky Times Ahead For Stratec (ETR:SBS)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Aggiornamento della narrazione • Jan 08
SBS: Index Exit And 2025 Margin Guidance Will Define Upside Potential
Analysts have trimmed their fair value estimate for Stratec from about €51.00 to roughly €44.96. This aligns with a recent reduction in the Street price target to €27 from €30 as they factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.Aggiornamento della narrazione • Dec 18
SBS: Margin Recovery Outlook Will Support Upside Despite Reduced Price Objective
Analysts have trimmed their price target on Stratec to EUR 27.00 from EUR 30.00, reflecting slightly more cautious assumptions on long term growth, a higher discount rate, and a modestly lower future P E multiple, despite marginally improved margin expectations. Analyst Commentary Bearish analysts have highlighted that the reduction in the price target to EUR 27.00 signals a more guarded stance on Stratec's medium to long term prospects, even as the rating on the shares remains unchanged at Hold.Aggiornamento della narrazione • Dec 04
SBS: Future Margin Gains Will Emerge As Cost Controls Take Hold
Analysts have modestly reduced their price target on Stratec, trimming it by EUR 3 to EUR 27. This reflects slightly lower long term return expectations while maintaining a cautious stance on the shares.Articolo di analisi • Nov 29
Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aggiornamento della narrazione • Nov 20
SBS: Margins Will Improve With Cost Management And Leadership Changes
The analyst price target for Stratec has been revised downward from €30 to €27. Analysts cited a slightly higher discount rate and modest changes in growth and profitability expectations as key drivers behind the adjustment.Articolo di analisi • Nov 11
Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Stratec SE ( ETR:SBS ) shareholders are probably feeling a little disappointed, since its shares fell 5.2% to €21.75 in...Articolo di analisi • Nov 07
Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding
Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 35% after a relatively good period beforehand. The drop...Aggiornamento della narrazione • Nov 03
SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures
Analysts have revised their price target for Stratec downward from €36.58 to €33.30, citing expectations of slower revenue growth and a slight decrease in profit margins. What's in the News Tanja Bücherl will join STRATEC SE's Board of Management as Chief Financial Officer effective November 1, 2025.Articolo di analisi • Sep 23
Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult
Stratec SE's ( ETR:SBS ) price-to-earnings (or "P/E") ratio of 25.3x might make it look like a sell right now compared...Aggiornamento della narrazione • Aug 23
Automation And Digitalization Will Transform Healthcare Diagnostics
Stratec’s consensus price target has been revised downward, primarily reflecting lowered forecasts for both revenue growth and net profit margin, resulting in a new fair value of €37.32. What's in the News Stratec increased its dividend to €0.60 per share for 2024 (previously €0.55), totaling €7.3 million to be distributed.Articolo di analisi • Jun 17
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued
Key Insights Stratec's estimated fair value is €36.05 based on 2 Stage Free Cash Flow to Equity Stratec is estimated to...Articolo di analisi • Apr 25
Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price
With a price-to-earnings (or "P/E") ratio of 30.8x Stratec SE ( ETR:SBS ) may be sending very bearish signals at the...
Nuova narrazione • Feb 09
Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence
Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize.Articolo di analisi • Jan 18
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stratec fair value estimate is €55.10 Stratec's €32.10 share...Articolo di analisi • Nov 09
With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For
Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 25% after a relatively good period beforehand. The drop...Articolo di analisi • Oct 26
Returns At Stratec (ETR:SBS) Appear To Be Weighed Down
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Articolo di analisi • May 11
Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
Key Insights Stratec to hold its Annual General Meeting on 17th of May Total pay for CEO Marcus Wolfinger includes...Articolo di analisi • Apr 11
Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Stratec SE's ( ETR:SBS ) dividend is being reduced from last year's payment covering the same period to €0.55 on the...Articolo di analisi • Apr 01
Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Stratec SE ( ETR:SBS ) filed its yearly result this time last week. The early...Articolo di analisi • Mar 28
Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
The board of Stratec SE ( ETR:SBS ) has announced it will be reducing its dividend by 43% from last year's payment of...Articolo di analisi • Dec 21
Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Key Insights Stratec's estimated fair value is €67.40 based on 2 Stage Free Cash Flow to Equity Stratec's €43.00 share...Articolo di analisi • Nov 03
Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Articolo di analisi • Oct 19
We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Jul 12
Return Trends At Stratec (ETR:SBS) Aren't Appealing
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Articolo di analisi • Jun 27
Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Key Insights Stratec's estimated fair value is €110 based on 2 Stage Free Cash Flow to Equity Stratec is estimated to...Rendimenti per gli azionisti
| SBS | DE Medical Equipment | DE Mercato | |
|---|---|---|---|
| 7D | 2.6% | 0.7% | 0.7% |
| 1Y | -37.3% | -26.5% | 2.0% |
Ritorno vs Industria: SBS ha avuto una performance inferiore rispetto al German Medical Equipment che ha registrato un rendimento -26.5 % nell'ultimo anno.
Rendimento vs Mercato: SBS ha avuto una performance inferiore al mercato German che ha registrato un rendimento 2 % nell'ultimo anno.
Volatilità dei prezzi
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Prezzo delle azioni stabile: SBS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di SBS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1979 | 1,343 | Marcus Wolfinger | www.stratec.com |
Stratec SE, insieme alle sue controllate, progetta e produce soluzioni di automazione e strumentazione nei settori della diagnostica in vitro e delle scienze della vita in Germania, nell'Unione Europea e a livello internazionale. Progetta e produce sistemi di analizzatori automatizzati per clienti del settore della diagnostica clinica e delle biotecnologie e offre materiali di consumo complessi per applicazioni diagnostiche e mediche. L'azienda, precedentemente nota come STRATEC Biomedical AG, ha cambiato nome in Stratec SE nel dicembre 2018.
Stratec SE Riepilogo dei fondamenti
| SBS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €214.92m |
| Utili (TTM) | -€242.00k |
| Ricavi(TTM) | €250.86m |
0.9x
Rapporto P/S-888.1x
Rapporto P/ESBS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SBS Conto economico (TTM) | |
|---|---|
| Ricavi | €250.86m |
| Costo del fatturato | €186.64m |
| Profitto lordo | €64.22m |
| Altre spese | €64.46m |
| Utili | -€242.00k |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Aug 14, 2026
| Utile per azione (EPS) | -0.02 |
| Margine lordo | 25.60% |
| Margine di profitto netto | -0.097% |
| Rapporto debito/patrimonio netto | 50.4% |
Come si è comportato SBS nel lungo periodo?
Vedi performance storica e confrontoDividendi
3.4%
Rendimento attuale del dividendo-3,014%
Rapporto di remunerazioneSBS paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di SBS| Stratec date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Jun 24 2026 |
| Data di pagamento dei dividendi | Jun 26 2026 |
| Giorni fino al dividendo Ex | 23 days |
| Giorni prima della data di pagamento dei dividendi | 25 days |
SBS paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di SBSAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/31 19:55 |
| Prezzo dell'azione a fine giornata | 2026/05/29 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Stratec SE è coperta da 11 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Michael Heider | Berenberg |
| Jan Koch | Deutsche Bank |
| Jan Koch | Deutsche Bank |